Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
231
-
Total 13F shares, excl. options
-
175M
-
Shares change
-
-2.18M
-
Total reported value, excl. options
-
$2.91B
-
Value change
-
-$42.1M
-
Put/Call ratio
-
0.58
-
Number of buys
-
83
-
Number of sells
-
-134
-
Price
-
$16.59
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q3 2020
287 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2020.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 231 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 175M shares
.
Largest 10 shareholders include Invesco Ltd. (35.7M shares), FMR LLC (19.6M shares), PRIMECAP MANAGEMENT CO/CA/ (18.9M shares), BlackRock Inc. (18M shares), VANGUARD GROUP INC (15.8M shares), WELLINGTON MANAGEMENT GROUP LLP (15.2M shares), MAVERICK CAPITAL LTD (5.68M shares), STATE STREET CORP (4.25M shares), Bellevue Group AG (3.63M shares), and FIRST TRUST ADVISORS LP (3.02M shares).
This table shows the top 231 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.